Bod is collaborating with world-leading experts

Bod is collaborating with a number of leading researchers, clinicians and institutions around the world, including:

Drug Science, UK

Drug Science is the leading independent scientific body on drugs in the UK, working to provide clear, evidence-based information on drugs.

Bod will be one of five companies to participate in Europe’s largest medicinal cannabis project, Project Twenty21.

Lambert Initiative for Cannabinoid Therapeutics, The University of Sydney

The Lambert initiative is an Australian first in the field of medicinal cannabinoids. Their aim is to optimise safe and effective cannabinoid therapeutics into mainstream medicine in Australia and beyond to deliver long overdue benefits for patients and to alleviate suffering, targeting a range of conditions including paediatric epilepsy, cancer, chronic pain, obesity, neurological, and mental health disorders.
Bod Medicinal Cannabis has been used in a number of the studies conducted by the Lambert Initiative.

University of Technology

Bod is working with a team of researchers from the University of Technology being led by Professor Stella Valenzuela who is one of the University’s leading Nanobiotechnology researchers and the Associate Head of School (Research) in the School of Life Sciences. The collaboration has resulted in the discovery of novel proteins that provide protective antioxidant effects that are now being investigated for their potential anti-ageing application in skin.

University of South Australia

Bod has entered collaboration with researchers from the University of South Australia’s School of Pharmacy and Medical Sciences to develop clinical trials to assess the safety and efficacy of Bod’s medicinal cannabis products. This collaboration will assist with ongoing product development and will provide valuable information for clinical practice and future research.

If you are interested in collaborating, have patients who would like to participate in current or future clinical trials or for general enquires, please contact us.